Key result
Early screening and cardioprotectants like dexrazoxane mitigate anthracycline-induced cardiotoxicity driven by oxidative injury.
Why the study?
Anthracycline use in cancer treatment is limited by dose-related cardiotoxicity, necessitating evaluation of screening and cardioprotective strategies.
Population
Adults and children with cancer receiving anthracycline chemotherapy
Comparison
Various anthracycline analogues and cardioprotective agents versus standard anthracycline use
Design
Review
Authors
Loading...
Screening may curb chronic anthracycline cardiomyopathy; leaves open optimal modalities and timing in modern regimens.
This review highlights strategies to mitigate anthracycline-induced cardiotoxicity, including early screening and the use of cardioprotective agents.
Nelson et al. (2001) conducted a review in Cancer. Anthracyclines was evaluated. Anthracycline-induced cardiotoxicity, primarily caused by oxidative injury, can be mitigated through early screening and the use of protective agents like dexrazoxane or less toxic analogues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: